文献速递脊柱关节炎

非戈替尼治疗活动性放射学及非放射学中轴型脊柱关节炎:OLINGUITO III期试验结果

Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies.
PubMed 文献 · Ann Rheum Dis · 2026-08-12

OLINGUITO III期试验包含两项国际随机双盲安慰剂对照研究,评估非戈替尼200 mg每日一次治疗对≥2种NSAIDs应答不足或不耐受的活动性放射学或非放射学中轴型脊柱关节炎患者的疗效与安全性。第16周时两项研究均达到主要终点ASAS40应答,非戈替尼组显著优于安慰剂组,疗效维持至第52周,总体耐受性良好。

要点

  • ASAS40改善最早见于第1周,且不受hs-CRP水平或既往bDMARD使用影响。

核心结论

  • 在全部axSpA谱系中,非戈替尼可快速、显著改善患者相关的中轴型脊柱关节炎体征和症状,且耐受性良好。

研究设计与样本

  • OLINGUITO为III期试验,包含两项国际、随机、双盲、安慰剂对照、平行组研究。
  • 纳入确诊放射学或非放射学axSpA且对≥2种NSAIDs应答不足或不耐受的患者,按1:1随机分配至非戈替尼200 mg或安慰剂每日一次至第16周,分层因素为hs-CRP水平和既往bDMARD使用。
  • 第16周后患者接受开放标签非戈替尼200 mg至第52周;≥65岁和/或具有预设危险因素的患者接受基于应答的剂量(100或200 mg)。
  • 放射学axSpA研究n=258,非放射学axSpA研究n=237。

主要发现

  • ASAS40改善最早见于第1周,且不受hs-CRP水平或既往bDMARD使用影响。
  • 两项研究中次要终点ASDAS和SPARCC MRI骶髂关节炎症均显著改善;放射学axSpA患者中BASFI和ASQoL亦显著改善。
  • 非戈替尼的改善维持至第52周并进一步增加。
  • 安全性事件:心肌梗死2例(安慰剂组n=1;安慰剂-非戈替尼组n=1),带状疱疹3例(安慰剂-非戈替尼组),恶性肿瘤(排除非黑色素瘤皮肤癌)4例(非戈替尼组n=3;安慰剂-非戈替尼组n=1)。

关键数值与推荐

  • 主要终点为第16周ASAS40应答。

临床怎么用

  • 对于对≥2种NSAIDs应答不足或不耐受的活动性放射学或非放射学axSpA患者,非戈替尼200 mg每日一次可考虑作为治疗选择。
  • 非戈替尼治疗早期(第1周)即可观察到ASAS40应答,且疗效不受hs-CRP水平或既往bDMARD使用影响。
  • 长期治疗至第52周疗效维持或进一步改善,但需关注带状疱疹、心肌梗死和恶性肿瘤等安全性事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to investigate the efficacy and safety of filgotinib, a JAK1 preferential inhibitor, in patients with axial spondyloarthritis (axSpA). METHODS: The phase 3 OLINGUITO trial comprises 2 international, randomised, double-blind, placebo (PBO)-controlled studies. Patients with an established diagnosis of radiographic (r) or nonradiographic (nr) axSpA and an inadequate response/intolerance to ≥2 nonsteroidal anti-inflammatory drugs were randomised 1:1 to filgotinib 200 mg or PBO once daily through week (W) 16 (double-blind period; stratified by high-sensitivity C-reactive protein [hs-CRP] level and prior biologic disease-modifying antirheumatic drug [bDMARD] use). After W16, patients received open-label filgotinib 200 mg through W52; patients ≥65 years and/or with prespecified risk factors received response-based dosing (100 or 200 mg). The primary (Assessment of SpondyloArthritis international Society ≥40% response [ASAS40 response]) and secondary efficacy endpoints were assessed at W16. Efficacy and safety were assessed through W52. RESULTS: At W16, the primary endpoint was met in both studies (ASAS40 response rates: r = axSpA [n = 258], 39.5% filgotinib vs 20.9% PBO [P = .001]; nr-axSpA [n = 237], 34.5% vs 17.8% [P = .003], respectively). ASAS40 improvements, irrespective of hs-CRP level/prior bDMARD use, were observed as early as W1. For secondary endpoints, significant improvements were seen in Axial Spondyloarthritis Disease Activity Score and Spondyloarthritis Research Consortium of Canada magnetic resonance imaging sacroiliac joint inflammation in both studies, and in Bath Ankylosing Spondylitis Functional Index and Ankylosing Spondylitis Quality of Life Questionnaire in patients with r-axSpA. Improvements with filgotinib were maintained/increased further through W52. Overall, 2 cases of myocardial infarction (PBO: n = 1; PBO-filgotinib: n = 1), 3 of herpes zoster (PBO-filgotinib), and 4 of malignancies (excluding nonmelanoma skin cancer; filgotinib: n = 3; PBO-filgotinib: n = 1) occurred. CONCLUSIONS: Across the whole spectrum of axSpA, filgotinib provided rapid and significant patient-relevant improvements in axSpA signs and symptoms and was well tolerated.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Baraliakos X, Maksymowych WP, Navarro-Compán V, et al. Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studies. Ann Rheum Dis. 2026. PMID: 42586909. doi:10.1016/j.ard.2026.06.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。